Craig-Hallum raised the firm’s price target on CVRx (CVRX) to $20 from $15 and keeps a Buy rating on the shares. The firm cites positive news for CVRx as Barostim stays in APC 1580 for 2025; reimbursement stays at $45. The firm is adjusting its numbers to account for Barostim reimbursement staying at $45K in 2025, which brings estimates higher. Its estimates do not come up fully with the magnitude of the ASP change, as Craig-Hallum is slightly moderating its volume growth expectations for 2025 to account for management commentary.
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVRX:
- CVRx announces outpatient payment for Barostim procedure in 2025
- CVRx price target raised to $15 from $12 at Lake Street
- CVRx price target raised to $16 from $13 at Piper Sandler
- CVRx price target raised to $17 from $15 at Canaccord
- CVRx Reports Strong Revenue Growth in Q3 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
